HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH

HighVista Strategies LLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 241.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 54,225 shares of the company’s stock after buying an additional 38,364 shares during the quarter. HighVista Strategies LLC owned approximately 0.13% of Dianthus Therapeutics worth $2,134,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Parkside Financial Bank & Trust raised its position in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the period. Bessemer Group Inc. boosted its position in shares of Dianthus Therapeutics by 7.8% during the 3rd quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock worth $635,000 after purchasing an additional 1,170 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at about $27,000. Finally, Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the 3rd quarter valued at about $64,000. 47.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DNTH. HC Wainwright increased their price target on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a research note on Monday, March 9th. Truist Financial raised their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 9th. Finally, Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $63.00 to $123.00 in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $115.33.

Dianthus Therapeutics Stock Down 3.1%

Dianthus Therapeutics stock opened at $77.86 on Monday. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $88.02. The company’s 50 day moving average price is $52.53 and its two-hundred day moving average price is $42.82. The stock has a market cap of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, CAO Edward Carr sold 43,682 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 200,430 shares of company stock worth $16,332,702 in the last quarter. 16.56% of the stock is currently owned by company insiders.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.